Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Purchases 1,483 Shares of Stock

Posted by Stacy Sanders on May 11th, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. bought 1,483 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were acquired at an average price of $24.98 per share, for a total transaction of $37,045.34. Following the completion of the transaction, the insider owned 6,325,914 shares in the company, valued at $158,021,331.72. This represents a 0.02% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Monday, May 11th, Ra Capital Management, L.P. bought 39,869 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.81 per share, for a total transaction of $989,149.89.
On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.46 per share, for a total transaction of $242,300.76.
On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Price Performance

Shares of NASDAQ COAG traded down $0.12 during midday trading on Monday, reaching $25.00. 239,335 shares of the company traded hands, compared to its average volume of 376,423. Hemab Therapeutics Holdings, Inc. has a 12 month low of $23.00 and a 12 month high of $36.61.